Trial explores regenerative macrophage therapy for liver disease
News
eXmoor and Anthony Nolan partner to streamline cell therapy development
Collaboration offers end-to-end support from donor sourcing to manufacturing
FDA approves LEQEMBI IQLIK for maintenance dosing in early Alzheimer’s disease
New subcutaneous autoinjector offers at-home treatment option for patients
Lilly receives UK approval for pirtobrutinib in relapsed blood cancers
MHRA grants conditional authorisation for treatment targeting mantle cell lymphoma
Akiram advances trial of targeted radiotherapy for solid tumours
Swedish biotech company Akiram Therapeutics has announced significant progress in its first clinical trial of AKIR001,...
Coya Therapeutics to progress trial of ALS treatment upon FDA approval
The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application from Coya...
Encare’s ERAS system gains Mayo Clinic qualification, strengthening global reach
Encare’s ERAS Interactive Audit System (EIAS) has earned qualification on the Mayo Clinic Platform_Solutions Studio –...
Johnny Cheng appointed as interim CEO of HUTCHMED
HUTCHMED has announced that Weiguo Su, CEO of the company, will take a leave of absence from his duties due to health...
Novartis blood disorder drug shows promise in late-stage trial
Novartis has reported that its experimental drug ianalumab met the primary goal in a phase 3 trial for primary immune...
Anne White to retire as head of Lilly Neuroscience after three decades at company
Eli Lilly and Company has announced that Anne White, executive vice president and president of Lilly Neuroscience,...
ANGLE partners with Myriad Genetics to explore blood-based cancer testing
ANGLE has announced a collaboration with Myriad Genetics to assess whether circulating tumour cell (CTC) DNA harvested from blood samples using ANGLE’s Parsortix system can be used alongside Myriad’s existing tissue-based diagnostic assays.
Friends of Cancer Research and MMS partner to improve interpretation of cancer trial survival data
Friends of Cancer Research has announced a new collaboration with global clinical research organisation, MMS, to develop decision frameworks that will help interpret interim overall survival (OS) data in oncology trials.
Upperton Pharma Solutions awarded grant to develop oral vaccine delivery with University of Oxford
Upperton Pharma Solutions has been awarded funding under the first VaxHub Sustainable Platform Funding Call to support...
FDA grants Breakthrough Therapy Designation to lung cancer therapy
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab...
Ogsiveo approved in EU for treatment of desmoid tumors
Merck’s therapy becomes first authorised option for aggressive soft tissue tumours
